Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d.